Bioptimus

News

Bioptimus raises $41m for its GenAI model for biology

AI startup Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.

News

Prof Jean-Phillipe Vert, Owkin's chief R&D officer

Bioptimus born with $35m for a foundation model for biology

A team of scientists formerly working at Google DeepMind and Owkin have joined forces to create Bioptimus, a start-up that will apply generative artificial intelligence (G

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks